Helius Medical Technologies (Nasdaq:HSDT) - 주가, 뉴스 및 분석

HSDT 주식 개요

신경 기술 회사인 헬리우스 메디컬 테크놀로지스는 신경 질환이나 외상으로 인한 증상 치료를 위한 비이식 기술을 개발, 라이선스 및 인수하는 데 주력하고 있습니다. 자세한 내용

HSDT 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

수익은 연간 28.64% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 7.8% 증가했습니다.

위험 분석

수익은 향후 3년간 연평균 19.7% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $2M )

cash runway 경력이 1년 미만입니다.

+ 3 더 많은 위험

Helius Medical Technologies, Inc. 경쟁사

Tivic Health Systems

NasdaqCM:TIVC

US$2.0m

Escalon Medical

OTCPK:ESMC

US$1.1m

Nuwellis

NasdaqCM:NUWE

US$4.4m

Sonendo

OTCPK:SONX.D

US$1.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Helius Medical Technologies
과거 주가
현재 주가	US$0.45
52주 최고치	US$9.50
52주 최저치	US$0.37
베타	1.61
11개월 변경	-7.98%
3개월 변경 사항	-39.57%
1년 변경 사항	-92.87%
33년 변화	-99.87%
5년 변화	-99.95%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Aug 23

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Aug 05

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Aug 18

주주 수익률

	HSDT	US Medical Equipment	US 마켓
7D	-5.7%	1.5%	2.2%
1Y	-92.9%	20.8%	31.6%

수익률 대 산업: HSDT 지난 1년 동안 20.8 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: HSDT 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is HSDT's price volatile compared to industry and market?
HSDT volatility
HSDT Average Weekly Movement	20.1%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: HSDT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: HSDT 의 주간 변동성( 20% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2014	22	Dane Andreeff	heliusmedical.com

신경 기술 회사인 헬리우스 메디컬 테크놀로지스는 신경 질환이나 외상으로 인한 증상 치료를 위한 비이식 기술을 개발, 라이선스 및 인수하는 데 주력하고 있습니다. 이 회사의 제품은 다발성 경화증으로 인한 보행 장애와 경증에서 중등도의 외상성 뇌 손상으로 인한 균형 장애를 단기적으로 치료하고 감독된 치료 운동과 함께 사용하기 위한 비수술 의료 기기인 휴대용 신경조절 자극기(Portable Neuromodulation Stimulator)입니다. 는 2014년에 설립되었으며 펜실베이니아주 뉴타운에 본사를 두고 있습니다.

Helius Medical Technologies, Inc. 기본 사항 요약

Helius Medical Technologies 의 수익과 매출은 시가총액과 어떻게 비교하나요?
HSDT 기본 통계
시가총액	US$1.62m
수익(TTM)	-US$8.86m
수익(TTM)	US$502.00k

3.2x

P/S 비율

-0.2x

P/E 비율

HSDT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
HSDT 손익 계산서(TTM)
수익	US$502.00k
수익 비용	US$518.00k
총 이익	-US$16.00k
기타 비용	US$8.84m
수익	-US$8.86m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.48
총 마진	-3.19%
순이익 마진	-1,764.74%
부채/자본 비율	0%

HSDT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

HSDT 주식 개요

보상

위험 분석

Helius Medical Technologies, Inc. 경쟁사

NasdaqCM:TIVC

US$2.0m

OTCPK:ESMC

US$1.1m

NasdaqCM:NUWE

US$4.4m

OTCPK:SONX.D

US$1.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Recent updates

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022

Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange

Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020)

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Consensus revenue estimates fall to US$333.0k

Helius Medical makes CEO, CFO appointments

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time

Full year 2020 earnings released: US$11.80 loss per share (vs US$12.99 loss in FY 2019)

Revenue and earnings beat expectations

Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million.

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

Helius Medical Technologies announces reverse stock split

Revenue beats expectations, earnings disappoint